Emmet

Emmet is a Cambridge-based biotechnology company focused on developing a novel class of programmable RNA therapies. Founded by industry veterans from Alnylam and Moderna, the company leverages a proprietary platform to engineer RNA molecules for precise gene regulation and protein expression. Emmet aims to address a wide range of diseases by overcoming current limitations in RNA delivery and stability. The company's technology is designed to provide more controlled and durable therapeutic effects compared to traditional RNA approaches. Emmet is backed by prominent venture capital firms, including Arch Venture Partners and F-Prime Capital. Currently in the pre-clinical stage, the company is building a pipeline of candidates targeting high-need therapeutic areas.